Barri Tablet 4 mg contains Baricitinib, an oral immunomodulatory medicine belonging to the Janus kinase (JAK) inhibitor class. It is primarily used for the treatment of moderate to severe rheumatoid arthritis and other inflammatory conditions where conventional therapies have shown inadequate response. By targeting key inflammatory pathways, Barri Tablet 4 mg helps reduce joint inflammation, pain, swelling, and stiffness, thereby improving physical function and quality of life.

Baricitinib is also recognized for its role in managing certain immune-mediated disorders under specialist supervision, due to its ability to selectively suppress overactive immune responses.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Baricitinib 4 mg

Therapeutic Class

Janus kinase (JAK) inhibitor
Disease-modifying antirheumatic drug (DMARD)

Indications

Barri Tablet 4 mg is indicated for:

• Moderate to severe rheumatoid arthritis in adults

• Patients with inadequate response or intolerance to one or more conventional DMARDs

• Use as monotherapy or in combination with methotrexate or other non-biologic DMARDs

• Other immune-mediated inflammatory conditions as prescribed by a physician

Pharmacology

Baricitinib selectively inhibits Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), intracellular enzymes that play a crucial role in cytokine-mediated signaling pathways. These pathways are involved in the pathogenesis of inflammatory and autoimmune diseases.

By inhibiting JAK1 and JAK2, Baricitinib interrupts the signaling of pro-inflammatory cytokines such as interleukins and interferons. This results in reduced inflammation, decreased immune cell activation, and alleviation of disease symptoms. The targeted mechanism allows effective control of inflammation while minimizing widespread immune suppression.

Dosage and Administration

Barri Tablet 4 mg is administered orally.

• Recommended dose: 4 mg once daily or as directed by a physician

• The tablet may be taken with or without food

• Dose adjustments may be required in patients with renal impairment or based on clinical response

Patients should follow medical advice strictly and should not alter the dose without consulting a healthcare professional.

Contraindications

Barri Tablet 4 mg is contraindicated in patients with:

• Known hypersensitivity to Baricitinib or any component of the formulation

• Severe active infections, including tuberculosis

Side Effects

Possible side effects associated with Barri Tablet 4 mg include:

• Upper respiratory tract infections

• Headache

• Nausea

• Elevated liver enzymes

• Increased cholesterol levels

Serious infections, thromboembolic events, and hematological abnormalities may occur rarely and require close medical monitoring.

Precautions and Warnings

• Patients should be screened for tuberculosis and viral hepatitis before initiating therapy

• Caution is advised in patients with a history of chronic or recurrent infections

• Regular monitoring of blood counts, liver function, and lipid profile is recommended

• Use with caution in elderly patients and those with cardiovascular risk factors

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Pregnancy and Lactation

Barri Tablet 4 mg should not be used during pregnancy unless clearly necessary, as adequate human data are limited. Breastfeeding is not recommended during treatment and for a period after discontinuation, as advised by a physician.

Storage Conditions

Store below 30°C in a dry place. Protect from light and moisture. Keep out of reach of children.

Mode of Action

Baricitinib works by inhibiting JAK1 and JAK2 enzymes, thereby blocking cytokine signaling pathways responsible for inflammation and immune dysregulation. This action helps control disease activity and prevent joint damage.